910546-52-0

Upstream product

• 325154-22-1 2-isopropyl-3-{2-[3-methoxy(propyloxy)]-4-methoxyphenyl}propionic acid 
• 1351987-20-6 C₂₁H₃₂O₅ 
• 1351987-19-3 C₂₁H₃₄O₆ 
• 109-19-3 butyl isovalerate 
• 172900-75-3 4-methoxy-3-(3-methoxypropoxy)benzaldehyde 
• 1351987-21-7 methyl-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutanoate 
• 1351987-18-2 butyl-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutanoate 
• 173433-57-3 (2S)-2-{[4-methoxy-3-(3-methoxypropoxy)phenyl]-methyl}-3-methylbutyric acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Relevant academic research and scientific papers

Convergent Synthesis of the Renin Inhibitor Aliskiren Based on C5-C6 Disconnection and CO2H-NH2 Equivalence

A novel synthesis of the renin inhibitor aliskiren based on an unprecedented disconnection between C5 and C6 was developed, in which the C5 carbon acts as a nucleophile and the amino group is introduced by a Curtius rearrangement, which follows a simultaneous stereocontrolled generation of the C4 and C5 stereogenic centers by an asymmetric hydrogenation. Operational simplicity, step economy, and a good overall yield makes this synthesis amenable to manufacture on scale.

Process for Producing Aliskiren

A new route of synthesis of the compound Aliskiren of formula (I), used in the treatment of hypertension, is described.

PROCESS FOR THE MANUFACTURE OF SUBSTITUTED PROPIONIC ACIDS

The invention concerns a process for the manufacture of substituted propionic acids comprising providing a substrate of formula (I): And subjecting the substrate to enantioselective hydrogenation under enantioselective hydrogenation conditions in the presence of an enantioselective hydrogenation catalyst comprising a catalyst ligand having a metallocene group with a chiral phosphorus or arsenic substituent to provide in enantiomeric excess a product of formula (II): or its enantiomer or if applicable its diastereomer.